NCT03024749

Brief Summary

Spinal arteriovenous fistulas (AVFs) and arteriovenous malformations (AVMs) are complex neurosurgical lesions that are very challenging to manage. Spinal vascular malformations account for 3%-4% of all intradural spinal cord mass lesions. Over the last few decades our understanding of these lesions has dramatically increased thanks to neuroimaging technology (e.g. spinal angiography and indocyanine green angiography). Various treatment modalities including conservative observation, endovascular embolization, microsurgical resection, radiation therapy, and combined therapies have been reported. The treatment for these AVMs and AVFs depends on their location, the type of malformation, the area of the spine involved, and the condition of the patient at the time of treatment. Due to the rarity of these spinal vascular lesions, reports of their management and outcomes have been limited to small series and case reports. And the rates of obliteration and outcomes are not satisfactory, especially the spinal AVMs. Spinal vascular lesions are rare but represent a formidable challenge for the treating neurosurgeon.The purpose of this study is to establish multimodality treatment mode and evaluate the anatomical cure rate and functional preservation rate.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
380

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2016

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2016

Completed
26 days until next milestone

First Submitted

Initial submission to the registry

December 27, 2016

Completed
23 days until next milestone

First Posted

Study publicly available on registry

January 19, 2017

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2018

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2019

Completed
Last Updated

June 6, 2017

Status Verified

June 1, 2017

Enrollment Period

2.1 years

First QC Date

December 27, 2016

Last Update Submit

June 4, 2017

Conditions

Keywords

Spinal Arteriovenous MalformationSpinal Arteriovenous Fistula

Outcome Measures

Primary Outcomes (1)

  • Change of the spinal cord function

    American Spinal Injury Association(ASIA) Score for evaluating the spinal cord function.Indexes (ASIA score) at baseline (1 day before operation) and 12 months follow-up will be collected, then the change from preoperative to 12 months follow-up will be assessed.

    1 day before operation and 12 months postoperative

Secondary Outcomes (5)

  • Anatomic obliteration rate

    3 months post operation

  • American Spinal Injury Association(ASIA) Score

    1 week, 3 months, 6 months, 12 months post operation

  • Modified Aminoff & Logue's Scale (mALS)

    1 week, 3 months, 6 months, 12 months post operation

  • Modified Denis Pain and Numbness Scale (mDPNS)

    1 week, 3 months, 6 months, 12 months post operation

  • Incidence of perioperative complications

    1 week

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients with spinal AVMs/AVFs

You may qualify if:

  • patient diagnosed with spinal vascular diseases including
  • intradural arteriovenous malformation,
  • intradural arteriovenous fistula,
  • dural arteriovenous fistula,
  • extradural arteriovenous malformation,
  • paravertebral arteriovenous malformation,
  • paravertebral arteriovenous fistula,
  • cobbs' syndrome,
  • other spinal arteriovenous metameric syndromes involve the spinal cord.
  • patient not received surgical or interventional treatment before
  • patient with normal cardiac, renal and hepatic function
  • patient capable of understanding the content of the patient information / Informed Consent Form
  • patient willing and able to participate in the registry

You may not qualify if:

  • patient received surgical treatment or interventional treatment before
  • patient is pregnant
  • patient allergic to iodine
  • patient unable to complete follow-up
  • patient with cerebral lesions
  • patient with other spinal lesions
  • patient with cardiac, renal or hepatic dysfunction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tao Hong

Beijing, China

RECRUITING

Related Publications (4)

  • Lee YJ, Terbrugge KG, Saliou G, Krings T. Clinical features and outcomes of spinal cord arteriovenous malformations: comparison between nidus and fistulous types. Stroke. 2014 Sep;45(9):2606-12. doi: 10.1161/STROKEAHA.114.006087. Epub 2014 Jul 15.

    PMID: 25028446BACKGROUND
  • Rangel-Castilla L, Russin JJ, Zaidi HA, Martinez-Del-Campo E, Park MS, Albuquerque FC, McDougall CG, Nakaji P, Spetzler RF. Contemporary management of spinal AVFs and AVMs: lessons learned from 110 cases. Neurosurg Focus. 2014 Sep;37(3):E14. doi: 10.3171/2014.7.FOCUS14236.

    PMID: 25175433BACKGROUND
  • Gross BA, Du R. Spinal glomus (type II) arteriovenous malformations: a pooled analysis of hemorrhage risk and results of intervention. Neurosurgery. 2013 Jan;72(1):25-32; discussion 32. doi: 10.1227/NEU.0b013e318276b5d3.

    PMID: 23096418BACKGROUND
  • Gross BA, Du R. Spinal pial (type IV) arteriovenous fistulae: a systematic pooled analysis of demographics, hemorrhage risk, and treatment results. Neurosurgery. 2013 Jul;73(1):141-51; discussion 151. doi: 10.1227/01.neu.0000429848.91707.73.

    PMID: 23615108BACKGROUND

MeSH Terms

Conditions

Spinal Cord Vascular Diseases

Condition Hierarchy (Ancestors)

Spinal Cord DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Zhang Hongqi, MD

    Neurosurgical Department, Xuanwu Hospital, Beijing

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
12 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Director of Neurosurgery

Study Record Dates

First Submitted

December 27, 2016

First Posted

January 19, 2017

Study Start

December 1, 2016

Primary Completion

December 31, 2018

Study Completion

December 31, 2019

Last Updated

June 6, 2017

Record last verified: 2017-06

Locations